ClinicalTrials.gg
WithdrawnNCT07353957Updated Nov 2, 2026

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

A Phase 2 interventional study of Petosemtamab + Pembrolizumab in Lung Cancer - Non Small Cell Squamous and Lung Cancer - Non Small Cell Non-Squamous, sponsored by Genmab. Withdrawn at 24 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Genmab · Phase 2, Interventional, and Treatment

Why this study was withdrawn
This study-level decision was based on the evolving treatment landscape and strategic portfolio considerations and is not related to any safety concern.
Updated Nov 2, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing pembrolizumab in Lung Neoplasms — 10 open to participants now, 22 under way, 9 of them phase 3. pembrolizumab · Lung Neoplasms.

Enrollment
38th of 39
0 · median 46
Started
2026
with 1 other
Phase 2
22 of 39
5 open now
Registered
38th of 39
by date

Among the 39 studies testing pembrolizumab in Lung Neoplasms, this one is the 38th largest by enrollment, is one of 2 that started in 2026, is one of 22 in phase 2, and was the 38th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

10 of the 39 studies testing pembrolizumab in Lung Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing pembrolizumab in Lung Neoplasms, or all of them as a file.
02

Study summary

The study will test the efficacy and safety of petosemtamab in combination with Pembrolizumab in first line patients with squamous non-small cell lung cancer and non-squamous non-small cell lung cancer.

03

Conditions studied

  • Lung Cancer - Non Small Cell Squamous
  • Lung Cancer - Non Small Cell Non-Squamous

Browse trials for

Keywords

  • squamous
  • lung cancer
  • non-squamous lung cancer
  • petosemtamab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide written and is willing and able to comply with all study procedures and requirements
  • Age ≥ 18 years at the signing of ICF
  • At least 1 as defined by 1.1
  • performance status of 0 or 1
  • ≥ 12 weeks, in the opinion of the Investigator
  • Adequate hematologic function
  • ≥ 60 mL/min calculated according to the Cockroft and Gault formula
  • Adequate liver function
  • Serum albumin ≥ 3 g/dL
  • Serum magnesium and corrected calcium, Grade ≤ 1 alteration
  • Participants of must agree to use highly effective contraception methods for the duration of study participation
  • confirmed (Stage IV) sqNSCLC with TPS ≥ 50%
  • No prior systemic treatment for metastatic disease
  • Testing is required per local SOC and availability of testing to document absence of actionable genomic tumor aberrations
  • Histologically confirmed metastatic (Stage IV) non-squamous NSCLC with PD-L1 TPS ≥ 50%

Exclusion criteria

Exclusion Criteria:

  • Has untreated and/or carcinomatous meningitis
  • Participation in an interventional clinical study with any drug within 4 weeks prior to the first dose of study treatment OR participation in any clinical study with petosemtamab at any time prior to the first dose of study treatment, regardless of whether petosemtamab was received
  • Participants who received prior treatment with a PD-(L)1 inhibitor
  • Participants who have received prior systemic chemotherapy, targeted or biological antineoplastic therapy for NSCLC
  • Any systemic anticancer therapy within 4 weeks prior to the first dose of study treatment
  • Major surgery or radiotherapy within 3 weeks prior to the first dose of study treatment. Participants who received prior radiotherapy to ≥ 25% of bone marrow are not eligible, regardless of when it was received.
  • Persistent Grade > 1 toxicities related to prior antineoplastic therapies using v5.0
  • History of reaction to any of the of petosemtamab or pembrolizumab
  • Unstable angina; history of congestive heart failure of Class II-IV criteria or serious cardiac arrhythmia requiring treatment (except atrial fibrillation, paroxysmal supraventricular tachycardia); or history of myocardial infarction within 6 months prior to the first dose of study treatment
  • History of prior within the last 5 years, with the exception of excised local cancer
  • Current dyspnea at rest of any origin or other diseases requiring continuous oxygen therapy, including participants with a history of ILD (eg, pneumonitis or pulmonary fibrosis) or evidence of ILD on baseline chest CT scan
  • Current serious illness or medical condition, including but not limited to uncontrolled active infection and clinically significant pulmonary, metabolic, or psychiatric disorders
  • Known infectious disease
  • Participants who are pregnant or breastfeeding.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    First line squamous non-small cell lung cancer patients

    Combination Product: Petosemtamab + Pembrolizumab

  • Experimental
    First line non-squamous non-small cell lung cancer patients

    Combination Product: Petosemtamab + Pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate per investigator assessment

    ORR was defined as the proportion of participants who had a complete response (CR) or partial response (PR) per RECIST v1.1.

    Time frame: Up to 4.5 years

Secondary outcomes

  1. Duration of response per Investigator assessment

    For participants with a confirmed CR or PR per RECIST v1.1, DOR was defined as the time from the date of first documented response of CR or PR per RECIST v1.1 to the date of first documented progression or death due to underlying cancer.

    Time frame: Up to 4.5 years

  2. Disease control rate as per investigator assessment

    DCR is defined as the proportion of participants with CR or PR or stable disease (SD) per RECIST 1.1.

    Time frame: Up to 4.5 years

  3. Clinical Benefit Rate as per investigator assessment

    CBR was defined as the proportion of participants with a CR or PR, or SD lasting ≥24 weeks per RECIST v1.1

    Time frame: Up to 4.5 years

  4. Progression free survival as per investigator assessment

    PFS was defined as the time from first dose to the first documented disease progression per RECIST v1.1 or death due to any cause.

    Time frame: Up to 4.5 years

  5. Overall survival

    OS was defined as the time from first dose to death due to any cause.

    Time frame: Up to 4.5 years

  6. Number of participants who experienced on treatment adverse events

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. Severity of AEs will be graded according to the NCI CTCAE version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening and Grade 5: death related to adverse event.

    Time frame: Up to 4.5 years

  7. Concentrations of petosemtamab predose and at end of infusion

    Predose and end of infusion plasma concentrations as measured from all individual plasma concentrations.

    Time frame: Up to 6-12 months

  8. Incidence and serum titers of anti-drug antibodies (ADAs) against petosemtamab

    The frequency and proportion of participants developing anti-drug antibodies.

    Time frame: Up to 6-12 months

07

Study locations

24 sites
  • Florida Cancer Specialists - North
    St. Petersburg, Florida 33701-4553, United States
  • Memorial Sloan Kettering Cancer Center
    Long Island City, New York 11101, United States
  • Tennessee Site 2
    Chattanooga, Tennessee 37403, United States
  • Tennessee Site 1
    Nashville, Tennessee 37209, United States
  • Virginia Site 2
    Blacksburg, Virginia 24060, United States
  • Virginia Site 1
    Fairfax, Virginia 22031, United States
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
  • Australia Site 1
    Frankston, Victoria 3199, Australia
  • CHU Brest Hopital la Cavale Blanche
    Brest, 29609, France
  • Centre Hospitalier Intercommunal de Creteil (CHIC)
    Créteil, 94000, France
  • ICM - Montpellier Cancer Institute
    Montpellier, 34298, France
  • Hopital Nord Laennec
    Nantes, 44093, France
  • Universita degli Studi di Firenze - Azienda Ospedaliero-Universitaria Careggi
    Florence, 50134, Italy
  • Leiden University Medical Center
    Leiden, 2333, Netherlands
  • Chungbuk National University Hospital
    Cheongju-si, 28645, South Korea
  • Kyungpook National University Chilgok Hospital
    Daegu, 41404, South Korea
  • Severance Hospital - Yonsei University Health System
    Seoul, 3722, South Korea
  • The Catholic University of Korea, St. Vincents Hospital
    Suwon, 16247, South Korea
  • START - Rioja
    Logroño, 26006, Spain
  • HC Hospitales SL
    Marbella, 29660, Spain
  • Hospital Quironsalud Malaga
    Málaga, 29004, Spain
  • Clinica Universidad de Navarra - Pamplona
    Pamplona, 31008, Spain
  • Hospital Universitario de Navarra
    Pamplona, 31008, Spain
  • Hospital Alvaro Cunqueiro
    Vigo, 36312, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for May 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2026
First posted
Jan 21, 2026
StartActual
Mar 27, 2026
Primary completionEst.
May 31, 2028
CompletionEst.
Feb 27, 2031
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
Merus B.V.→Genmab
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Sponsor Merus B.V.→Genmab
    + 4 other changes: identifiers, verification date, site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07353957
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Mar 27, 2026
Primary completion
May 31, 2028 (estimated)
Completion
Feb 27, 2031 (estimated)
Last update
Nov 2, 2026

Study contacts

Study Official
study director · Genmab

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Petosemtamab · Pembrolizumab

Start the discussion